Showing 1551-1560 of 1774 results for "".
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officerhttps://modernod.com/news/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer/2480519/Aerie Pharmaceuticals announced that Raj Kannan will join the company as Chief Executive Officer and a director, effective December 20, 2021. “On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search pro
- Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunologyhttps://modernod.com/news/aramis-biosciences-launches-to-address-unmet-needs-in-ocular-immunology/2480514/Aramis Biosciences announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including i
- CoFi Announces 300 Eye Care Practices Now Use CoFi’s Compliant Co-Management Payments Tool for Ophthalmology Procedureshttps://modernod.com/news/cofi-announces-300-eye-care-practices-now-use-cofis-compliant-co-management-payments-tool-for-ophthalmology-procedures/2480490/CoFi, a provider of a multi-party payments platform for elective medical procedures, announced the growing adoption of its co-management payment solution for ophthalmology procedures with more than 300 practices now using CoFi. Throughout ophthalmology, there i
- Spherix Global Insights Introduces Ophthalmology to Suite of Independent Market Research and Intelligence Serviceshttps://modernod.com/news/spherix-global-insights-introduces-ophthalmology-to-suite-of-independent-market-research-and-intelligence-services/2480450/Spherix Global Insights, a market research firm providing independent coverage of select specialty markets, officially cut the ribbon on their ophthalmology franchise. Spherix derives actionable insights from its frequent, commercially-focused, primary market research, which i
- Researchers Discovery New Type of Nerve Cell in the Retinahttps://modernod.com/news/researchers-discovery-new-type-of-nerve-cell-in-the-retina/2480422/Scientists at the John A. Moran Eye Center at the University of Utah have discovered a new type of nerve cell, or neuron, in the retina. In the central nervous system a complex circuitry of neurons communicate with each other to relay sensory and motor information; so-called i
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I